← Eichor
Condition: Cdk4 6 Inhibitor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cdk4 6 Inhibitor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Phase 2 · 7 location(s) · Abramson Cancer Center at Penn Medicine · NCT04841148A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06947811Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Phase 2 · 1 location(s) · Dartmouth-Hitchcock Medical Center · NCT05933395Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic
Phase 2 · 2 location(s) · Fujian Cancer Hospital · NCT07581834A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Phase 1/Phase 2 · 15 location(s) · Tango Therapeutics, Inc. · NCT06810544Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pe
Phase 1 · 7 location(s) · National Cancer Institute (NCI) · NCT05372640Abemaciclib in Newly Diagnosed Meningioma Patients
Phase 2 · 1 location(s) · Nader Sanai · NCT05940493Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT05536128Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction
Phase 1 · 2 location(s) · University of Utah · NCT04315233Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients Wi
Phase N/A · 6 location(s) · AstraZeneca · NCT06417801A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Le
Phase 3 · 232 location(s) · Hoffmann-La Roche · NCT06790693A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Ca
Phase 2 · 1 location(s) · Fudan University · NCT07666555Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Phase 1 · 2 location(s) · Lebanese University · NCT06307249Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05759546Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (
Phase 2 · 188 location(s) · National Cancer Institute (NCI) · NCT06126276A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer
Phase 3 · 338 location(s) · Eli Lilly and Company · NCT07174336Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06176534Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins
Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT03310879Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Phase N/A · 1 location(s) · Wenjin Yin · NCT07180056Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06197581Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Br
Phase 2 · 72 location(s) · MedSIR · NCT06486883Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic
Phase 2/Phase 3 · 22 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05860465Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Phase 2 · 1 location(s) · University of California, San Diego · NCT07227233Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3 · 99 location(s) · MedSIR · NCT06382948A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 19 location(s) · NiKang Therapeutics, Inc. · NCT06586957Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
Phase N/A · 1 location(s) · Institute of Oncology Ljubljana · NCT06650423
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.